News & Events

• October 19, 2021 - October 20, 2021
  

  REGISTER NOW | 2021 INC Scientific Meeting

  C-Path’s International Neonatal Consortium will host its two-day annual scientific meeting in a virtual format, October 19-20, 2021.

• September 14, 2021
  

  REGISTER NOW | 2021 RDCA-DAP® Workshop

    The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) is an FDA-funded initiative with the goal of accelerating therapy development across rare diseases. The platform serves as a centralized and standardized infrastructure to host and share rare diseases data, to support and accelerate rare disease innovation. Join us for the RDCA-DAP 2021 Virtual Workshop,......
• August 25, 2021
  

  WEBINAR | Alternative Solutions in Safety Assessment

  When: August 25, 2021, 10 – 11:30 a.m. ET C-Path’s Predictive Safety Testing Consortium (PSTC) invites you to this free webinar, the second in its 15th anniversary educational webinar series, to explore the use of alternative solutions in safety assessment in drug development, including microphysiological systems (MPS) and In Vitro models. Pre-recorded presentations will provide an overview......
• August 17, 2021
  

  View Now | C-Path Neuroscience Program Webinar – NfL in Neurodegenerative Diseases

  C-Path’s Neuroscience Program hosted its first webinar on August 17, 2021. This webinar brought together more than 330 members, representatives and partners from pharmaceutical industries, academic experts, government and regulatory agencies, and patient advocacy groups.

• July 21, 2021
  

  View Now | How RDCA-DAP Can Help Inform Optimal Trial Design in Progressive Rare Disease

  When: July 21, 2021, 12 p.m. ET

  Case Study: Northstar Ambulatory Assessment as an outcome assessment in Duchenne muscular dystrophy

  Presenters: Varun Aggarwal, PhD, Director, Statistical and Mathematical Medicine, Quantitative Medicine; Kevin Krudys, PhD, Office of Clinical Pharmacology, FDA

  RDCA-DAP team: Jeff Barrett, PhD, FCP, Senior Vice President, RDCA-DAP Lead; Alexandre Bétourné, PhD, PharmD, Scientific Director, RDCA-DAP